Epibiotech CEO Sung Jong-hyeok said that through the presentation of the results of the non-clinical test conducted by the company, it was confirmed that the number of hairs increased by 40% and the hair thickness by 30% after 1 month after transplantation of human dermal papilla cells in pig skin. He also explained that the non-clinical toxicity test of EPI-001, a dermal papilla cell pipeline, was completed in June, and that it will apply for an IND in the second half of the year and enter the phase 1 clinical trial in 2023.
에피바이오텍-연세대 종합약학연구소,탈모 혁신신약 개발 심포지엄 성료 - 팜뉴스
탈모치료제 전문 연구개발 기업 에피바이오텍(대표 성종혁)이 연세대학교 종합약학연구소와 공동 주최한 '탈모 치료를 위한 혁신 약물 개발(Innovative drugwww.pharmnews.com
Epibiotech is in South Korea. If Epibiotech applies for the IND in South Korea maybe the approval process is shorter in South Korea than the US FDA process.
